149 related articles for article (PubMed ID: 8167347)
1. Ability of the orally effective iron chelators dimethyl- and diethyl-hydroxypyrid-4-one and of deferoxamine to restore sarcolemmal thiolic enzyme activity in iron-loaded heart cells.
Link G; Pinson A; Hershko C
Blood; 1994 May; 83(9):2692-7. PubMed ID: 8167347
[TBL] [Abstract][Full Text] [Related]
2. Role of iron in the potentiation of anthracycline cardiotoxicity: identification of heart cell mitochondria as a major site of iron-anthracycline interaction.
Link G; Tirosh R; Pinson A; Hershko C
J Lab Clin Med; 1996 Mar; 127(3):272-8. PubMed ID: 9273360
[TBL] [Abstract][Full Text] [Related]
3. Iron loading of cultured cardiac myocytes modifies sarcolemmal structure and increases lysosomal fragility.
Link G; Pinson A; Hershko C
J Lab Clin Med; 1993 Jan; 121(1):127-34. PubMed ID: 8426074
[TBL] [Abstract][Full Text] [Related]
4. Cardioprotective effect of alpha-tocopherol, ascorbate, deferoxamine, and deferiprone: mitochondrial function in cultured, iron-loaded heart cells.
Link G; Konijn AM; Hershko C
J Lab Clin Med; 1999 Feb; 133(2):179-88. PubMed ID: 9989770
[TBL] [Abstract][Full Text] [Related]
5. Iron chelation studies using desferrioxamine and the potential oral chelator, 1,2-dimethyl-3-hydroxypyrid-4-one, in normal and iron loaded rats.
Kontoghiorghes GJ; Sheppard L; Hoffbrand AV; Charalambous J; Tikerpae J; Pippard MJ
J Clin Pathol; 1987 Apr; 40(4):404-8. PubMed ID: 3584483
[TBL] [Abstract][Full Text] [Related]
6. Identification of thiolic sarcolemmal proteins as a primary target of iron toxicity in cultured heart cells.
Link G; Pinson A; Hershko C
Adv Exp Med Biol; 1994; 356():267-76. PubMed ID: 7887231
[No Abstract] [Full Text] [Related]
7. Antioxidant and free radical scavenging activities of the iron chelators pyoverdin and hydroxypyrid-4-ones in iron-loaded hepatocyte cultures: comparison of their mechanism of protection with that of desferrioxamine.
Morel I; Cillard J; Lescoat G; Sergent O; Pasdeloup N; Ocaktan AZ; Abdallah MA; Brissot P; Cillard P
Free Radic Biol Med; 1992 Nov; 13(5):499-508. PubMed ID: 1334028
[TBL] [Abstract][Full Text] [Related]
8. Studies of in vivo iron mobilization by chelators in the ferrocene-loaded rat.
Florence A; Ward RJ; Peters TJ; Crichton RR
Biochem Pharmacol; 1992 Sep; 44(6):1023-7. PubMed ID: 1417929
[TBL] [Abstract][Full Text] [Related]
9. Iron mobilization from myocardial cells by 3-hydroxypyridin-4-one chelators: studies in rat heart cells in culture.
Hershko C; Link G; Pinson A; Peter HH; Dobbin P; Hider RC
Blood; 1991 May; 77(9):2049-53. PubMed ID: 2018841
[TBL] [Abstract][Full Text] [Related]
10. Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture.
Link G; Konijn AM; Breuer W; Cabantchik ZI; Hershko C
J Lab Clin Med; 2001 Aug; 138(2):130-8. PubMed ID: 11477380
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminium chelating drugs.
Kontoghiorghes GJ
Toxicol Lett; 1995 Oct; 80(1-3):1-18. PubMed ID: 7482575
[TBL] [Abstract][Full Text] [Related]
12. Effect of novel 1-alkyl-3-hydroxy-2-methylpyrid-4-one chelators on uptake and release of iron from macrophages.
Brock JH; Licéaga J; Arthur HM; Kontoghiorghes GJ
Am J Hematol; 1990 May; 34(1):21-5. PubMed ID: 2327400
[TBL] [Abstract][Full Text] [Related]
13. A comparison of the iron-clearing properties of 1,2-dimethyl-3-hydroxypyrid-4-one, 1,2-diethyl-3-hydroxypyrid-4-one, and deferoxamine.
Bergeron RJ; Streiff RR; Wiegand J; Luchetta G; Creary EA; Peter HH
Blood; 1992 Apr; 79(7):1882-90. PubMed ID: 1558978
[TBL] [Abstract][Full Text] [Related]
14. Comparative study of the protective effect between deferoxamine and deferiprone on chronic iron overload induced cardiotoxicity in rats.
Emara AM; El Kelany RS; Moustafa KA
Hum Exp Toxicol; 2006 Jul; 25(7):375-85. PubMed ID: 16898166
[TBL] [Abstract][Full Text] [Related]
15. Chelation of aluminium by combining DFO and L1 in rats.
Blanusa M; Prester L; Varnai VM; Pavlović D; Kostial K; Jones MM; Singh PK
Toxicology; 2000 Jul; 147(3):151-6. PubMed ID: 10924797
[TBL] [Abstract][Full Text] [Related]
16. Multidentate pyridinones inhibit the metabolism of nontransferrin-bound iron by hepatocytes and hepatoma cells.
Chua AC; Ingram HA; Raymond KN; Baker E
Eur J Biochem; 2003 Apr; 270(8):1689-98. PubMed ID: 12694182
[TBL] [Abstract][Full Text] [Related]
17. Competition between deferiprone, desferrioxamine and other chelators for iron and the effect of other metals.
Sheppard LN; Kontoghiorghes GJ
Arzneimittelforschung; 1993 Jun; 43(6):659-63. PubMed ID: 8352819
[TBL] [Abstract][Full Text] [Related]
18. In vivo evaluation of hydroxypyridone iron chelators in a mouse model.
Gyparaki M; Porter JB; Hirani S; Streater M; Hider RC; Huehns ER
Acta Haematol; 1987; 78(2-3):217-21. PubMed ID: 3120475
[TBL] [Abstract][Full Text] [Related]
19. EPR study of antioxidant activity of the iron chelators pyoverdin and hydroxypyrid-4-one in iron-loaded hepatocyte culture: comparison with that of desferrioxamine.
Morel I; Sergent O; Cogrel P; Lescoat G; Pasdeloup N; Brissot P; Cillard P; Cillard J
Free Radic Biol Med; 1995 Feb; 18(2):303-10. PubMed ID: 7744315
[TBL] [Abstract][Full Text] [Related]
20. The iron chelators desferrioxamine and 1-alkyl-2-methyl-3-hydroxypyrid-4-ones inhibit vascular prostacyclin synthesis in vitro.
Jeremy JY; Kontoghiorghes GJ; Hoffbrand AV; Dandona P
Biochem J; 1988 Aug; 254(1):239-44. PubMed ID: 3140797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
